title: The price of tenofovir-emtricitabine undermines the cost-effectiveness and advancement of pre-exposure prophylaxis.
authors: Samuel B
authors: SB
authors: Keller
authors: Davey M
authors: DM
authors: Smith
mesh_terms: D000225:Adenine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000191:economics; D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000191:economics; D000998:Antiviral Agents / Q000008:administration & dosage / Q000191:economics*; D003362:Cost-Benefit Analysis; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000191:economics; D016527:Drug Costs / Q000706:statistics & numerical data*; D004359:Drug Therapy, Combination / Q000191:economics; D000068679:Emtricitabine; D015658:HIV Infections / Q000191:economics* / Q000517:prevention & control; D006801:Humans; D018803:Models, Economic; D063065:Organophosphonates / Q000008:administration & dosage / Q000191:economics*; D000068698:Tenofovir
chemical_list: D019380:Anti-HIV Agents; D000998:Antiviral Agents; D063065:Organophosphonates; D003841:Deoxycytidine; D000068698:Tenofovir; D000068679:Emtricitabine; D000225:Adenine